FDA approves sleep apnea implant device

The FDA approved an implantable device, Respicardia’s Remede System, which helps fight moderate to severe cases of central sleep apnea, a condition where the brain doesn’t send proper signals to the muscles that control breathing during sleep.

Advertisement

The device consists of an implantable battery pack and thin wires that are inserted into blood vessels in the upper chest near the nerve that is responsible for sending signals to the diaphragm to fuel breathing. If the device detects the patient is not breathing, it will stimulate the nerve to move the diaphragm to initiate normal breathing.

The Remede System is not intended for use in patients who need MRI scans, have an active infection or are diagnosed with obstructive sleep apnea, a condition where the upper airway is partially or completely blocked. 

More articles on supply chain:
FDA commissioner: High drug prices are a ‘public health concern the FDA should address’
Judge ruling allows drug ‘price gouging’ law to take effect in Maryland
Rite Aid names former Walgreens executive as president, COO

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.